BIOMAT Database Logo BIOMAT Database Logo

Mutant botrocetin-2 inhibits von Willebrand factor-induced platelet agglutination. 2017

T Matsui, and A Hori, and J Hamako, and F Matsushita, and Y Ozeki, and Y Sakurai, and M Hayakawa, and M Matsumoto, and Y Fujimura
Clinical Laboratory Medicine, Graduate School of Health Sciences, Fujita Health University School of Health Sciences, Toyoake, Japan.

Essentials Botrocetin-2 (Bot2) binds to von Willebrand factor (VWF) and induces platelet agglutination. We identified Bot2 residues that are required for binding to VWF and glycoprotein (GP) Ib. We produced a mutant Bot2 that binds to VWF but inhibits platelet agglutination. Mutant Bot2 could be used as a potential anti-thrombotic reagent to block VWF-GPIb interaction. Background Botrocetin-2 (Bot2) is a botrocetin-like protein composed of α and β subunits that have been cloned from the snake Bothrops jararaca. Bot2 binds specifically to von Willebrand factor (VWF), and the complex induces glycoprotein (GP) Ib-dependent platelet agglutination. Objectives To exploit Bot2's VWF-binding capacity in order to attempt to create a mutant Bot2 that binds to VWF but inhibits platelet agglutination. Methods and Results Several point mutations were introduced into Bot2 cDNA, and the recombinant protein (recombinant Bot2 [rBot2]) was purified on an anti-botrocetin column. The mutant rBot2 with either Ala at Asp70 in the β subunit (Aspβ70Ala), or Argβ115Ala and Lysβ117Ala, showed reduced platelet agglutination-inducing activity. rBot2 with Aspβ70Ala showed little binding activity towards immobilized VWF on an ELISA plate, whereas rBot2 with Argβ115Ala/Lysβ117Ala showed reduced binding activity towards GPIb (glycocalicin) after forming a complex with VWF. rBot2 point-mutated to oppositely charged Glu at both Argβ115 and Lysβ117 showed normal binding activity towards VWF but no platelet-agglutinating activity. Furthermore, this doubly mutated protein inhibited ristocetin-induced or high shear stress-induced platelet aggregation, and restrained thrombus formation under flow conditions. Conclusions Asp70 in the β subunit of botrocetin is important for VWF binding, and Arg115 and Lys117 in the β subunit are essential for interaction with GPIb. Doubly mutated rBot2, with Argβ115Glu and Lysβ117Glu, repels GPIb and might have potential as an antithrombotic reagent that specifically blocks VWF function. This is the first report on an artificial botrocetin that can inhibit the VWF-GPIb interaction.

UI MeSH Term Description Entries
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D003435 Crotalid Venoms Venoms from snakes of the subfamily Crotalinae or pit vipers, found mostly in the Americas. They include the rattlesnake, cottonmouth, fer-de-lance, bushmaster, and American copperhead. Their venoms contain nontoxic proteins, cardio-, hemo-, cyto-, and neurotoxins, and many enzymes, especially phospholipases A. Many of the toxins have been characterized. Bothrops Venom,Crotalidae Venoms,Pit Viper Venoms,Rattlesnake Venoms,Crotactin,Crotalid Venom,Crotalin,Crotaline Snake Venom,Crotalotoxin,Crotamin,Pit Viper Venom,Rattlesnake Venom,Snake Venom, Crotaline,Venom, Bothrops,Venom, Crotalid,Venom, Crotaline Snake,Venom, Pit Viper,Venom, Rattlesnake,Venoms, Crotalid,Venoms, Crotalidae,Venoms, Pit Viper,Venoms, Rattlesnake,Viper Venom, Pit
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014841 von Willebrand Factor A high-molecular-weight plasma protein, produced by endothelial cells and megakaryocytes, that is part of the factor VIII/von Willebrand factor complex. The von Willebrand factor has receptors for collagen, platelets, and ristocetin activity as well as the immunologically distinct antigenic determinants. It functions in adhesion of platelets to collagen and hemostatic plug formation. The prolonged bleeding time in VON WILLEBRAND DISEASES is due to the deficiency of this factor. Factor VIII-Related Antigen,Factor VIIIR-Ag,Factor VIIIR-RCo,Plasma Factor VIII Complex,Ristocetin Cofactor,Ristocetin-Willebrand Factor,von Willebrand Protein,Factor VIII Related Antigen,Factor VIIIR Ag,Factor VIIIR RCo,Ristocetin Willebrand Factor

Related Publications

T Matsui, and A Hori, and J Hamako, and F Matsushita, and Y Ozeki, and Y Sakurai, and M Hayakawa, and M Matsumoto, and Y Fujimura
Identification and recombinant analysis of botrocetin-2, a snake venom cofactor for von Willebrand factor-induced platelet agglutination.
July 2012, Biochemistry,
T Matsui, and A Hori, and J Hamako, and F Matsushita, and Y Ozeki, and Y Sakurai, and M Hayakawa, and M Matsumoto, and Y Fujimura
Role of botrocetin in platelet agglutination: formation of an activated complex of botrocetin and von Willebrand factor.
August 1989, Blood,
T Matsui, and A Hori, and J Hamako, and F Matsushita, and Y Ozeki, and Y Sakurai, and M Hayakawa, and M Matsumoto, and Y Fujimura
Von Willebrand factor, polycations, and platelet agglutination.
January 1980, Thrombosis research,
T Matsui, and A Hori, and J Hamako, and F Matsushita, and Y Ozeki, and Y Sakurai, and M Hayakawa, and M Matsumoto, and Y Fujimura
ADP-induced inhibition of von Willebrand factor-mediated platelet agglutination.
May 1976, The American journal of physiology,
T Matsui, and A Hori, and J Hamako, and F Matsushita, and Y Ozeki, and Y Sakurai, and M Hayakawa, and M Matsumoto, and Y Fujimura
Botrocetin- and polybrene-induced platelet aggregation in platelet-type von Willebrand disease.
February 1985, American journal of hematology,
T Matsui, and A Hori, and J Hamako, and F Matsushita, and Y Ozeki, and Y Sakurai, and M Hayakawa, and M Matsumoto, and Y Fujimura
A template-assembled synthetic protein surface mimetic of the von Willebrand factor A1 domain inhibits botrocetin-induced platelet aggregation.
June 2004, Chembiochem : a European journal of chemical biology,
T Matsui, and A Hori, and J Hamako, and F Matsushita, and Y Ozeki, and Y Sakurai, and M Hayakawa, and M Matsumoto, and Y Fujimura
Species specificity in von Willebrand factor-supported platelet agglutination.
January 1981, Annals of the New York Academy of Sciences,
T Matsui, and A Hori, and J Hamako, and F Matsushita, and Y Ozeki, and Y Sakurai, and M Hayakawa, and M Matsumoto, and Y Fujimura
Crystal structure of the von Willebrand factor modulator botrocetin.
January 2001, Biochemistry,
T Matsui, and A Hori, and J Hamako, and F Matsushita, and Y Ozeki, and Y Sakurai, and M Hayakawa, and M Matsumoto, and Y Fujimura
Agglutination of platelet-type von Willebrand's disease platelets by bovine von Willebrand factor.
April 1985, Thrombosis and haemostasis,
T Matsui, and A Hori, and J Hamako, and F Matsushita, and Y Ozeki, and Y Sakurai, and M Hayakawa, and M Matsumoto, and Y Fujimura
Enhanced botrocetin-induced type IIB von Willebrand factor binding to platelet glycoprotein Ib initiates hyperagglutination of normal platelets.
April 1990, American journal of hematology,
Copied contents to your clipboard!